In the Snyder et al. cohort [29], an advanced melanoma anti-CTLA-4-treated cohort (Additional file 2: Fig. S5A), and in the Mariathasan et al. cohort [22], a metastatic urothelial cancer anti-PD-L1-treated cohort (Additional file 2: Fig. S5B), the survival time of patients in the low-risk group was significantly longer than that of patients in the high-risk group (P < 0.05), which was consistent with the results obtained for the training cohort. The gene discussed is CD274; the disease is melanoma.